A recent study published inLancet Diabetes & AMP;EndocrinologyHe has revealed that the most popular drugs against diabetes and obesity, such as semagglutida (Ozempic, Wegovy), Dreamaglutida (Trulicity) and Liraglutida (Victaza), also have protective effects for kidneys.🌟

What does this discovery mean?

These medications, known as agonists of the GLP-1 receiver, originally designed to treat type 2 diabetes, have proven effective for:

  • Reduce the risk of renal failure by 16%.
  • Decrease the worsening of renal function by 22%.
  • Reduce the combined risk of renal failure, deterioration of renal function and death due to kidney disease by 19%.

In addition, the study confirms the already known cardiovascular benefits of these drugs, including a 14% reduction in the risk of death due to cardiovascular causes and 13% in general mortality.

Why is this advance so important?

Chronic kidney disease affects850 million people around the world, being the tenth cause of death globally, and it is expected to occupy the fifth place by 2050. This discovery represents a great advance, since it is the first clear evidence that the agonists of the GLP-1 receiver can protect against insufficiencyrenal and terminal renal disease.

How do agonists GLP-1 work?

These medications mimic the action of a hormone called peptide similar to glucagon-1, which helps:

  • Stimulate insulin production.
  • Reduce blood sugar levels.
  • Slow down digestion, increase satiety and reduce appetite.

Originally developed to treat diabetes, they have subsequently revealed as effective treatments against obesity, and now as a promising option to protect the kidneys.

A global impact for multiple conditions

Professor Sunil Badve, the main author of the study, highlights that these drugs have a key role not only in the treatment of diabetes, but also in the management of conditions such as obesity, cardiovascular disease and chronic renal disease.This finding could change the treatment approach for millions of people in the world.

A hopeful future

This discovery reinforces the potential of GLP-1 agonists as multifunctional treatments that not only improve the quality of life of people with diabetes and obesity, but also offer new hope for those who face the risk of renal complications.

If you have any experience or doubts about these treatments, share with us in the forum!